

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.org) on Apr 12, 2025

## MC-38

RRID:CVCL\_B288

Type: Cell Line

### Proper Citation

(Ubigenes Cat# YC-A002, RRID:CVCL\_B288)

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_B288](https://web.expasy.org/cellosaurus/CVCL_B288)

**Proper Citation:** (Ubigenes Cat# YC-A002, RRID:CVCL\_B288)

**Sex:** Female

**Defining Citation:** [PMID:1149045](#), [PMID:1255804](#), [PMID:16320114](#), [PMID:25277546](#), [PMID:25434994](#)

**Comments:** Caution: The authors of PubMed=25434994 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line MCA38. Their submitted DNA sequence (KM820832.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 406'.  
Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Mitochondrial genome sequenced.

**Category:** Cancer cell line

**Name:** MC-38

**Synonyms:** MCA-38, MCA 38, MCA38, MC38, Mouse Colon 38, Murine Carcinoma-38, Colon-38, Colon 38, Colon38, C38

**Cross References:** BTO:BTO\_0004163, CCRID:1101MOU-PUMC000523, ChEMBL-Cells:ChEMBL3307696, ChEMBL-Targets:ChEMBL612821, CLS:305223, Kerfast:ENH204-FP, Lonza:893, Millipore:SCC172, PubChem\_Cell\_line:CVCL\_B288, Ubigenes:YC-A002, Wikidata:Q54904168

**ID:** CVCL\_B288

**Vendor:** Ubigen

**Catalog Number:** YC-A002

**Record Creation Time:** 20250131T201319+0000

**Record Last Update:** 20250131T202913+0000

---

## Ratings and Alerts

No rating or validation information has been found for MC-38.

No alerts have been found for MC-38.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 1314 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Xie J, et al. (2024) Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer. *iScience*, 27(4), 109612.

Kim Y, et al. (2024) Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. *Cell host & microbe*, 32(8), 1380.

Guo Y, et al. (2024) S100a8/a9 regulated by LPS/TLR4 axis plays an important role in Salmonella-based tumor therapy and host defense. *International journal of cancer*, 155(11), 2080.

Lee KJ, et al. (2024) IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy. *Cell reports. Medicine*, 5(5), 101567.

Funauchi M, et al. (2024) Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. *International journal of cancer*, 154(3), 425.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Djajawi TM, et al. (2024) PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity. *Cell reports*, 43(3), 113831.

Zhang C, et al. (2024) Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation. *Cell death discovery*, 10(1), 41.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Singh A, et al. (2024) Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. *Cancer immunology, immunotherapy : CII*, 73(1), 16.

Peng Y, et al. (2024) Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy. *International journal of cancer*, 154(7), 1285.

Memon D, et al. (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. *Cancer cell*, 42(2), 209.

Trimaglio G, et al. (2024) The C-type lectin DCIR contributes to the immune response and pathogenesis of colorectal cancer. *Scientific reports*, 14(1), 7199.

Cheng S, et al. (2024) Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy. *Cell reports. Medicine*, 5(1), 101355.

Sun J, et al. (2024) Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring. *Nature metabolism*, 6(4), 741.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. *Cell reports*, 43(9), 114690.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. *Cell*, 187(11), 2690.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. *Molecular cancer therapeutics*, 23(4), 421.

Zhou W, et al. (2024) Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. *Cell reports*, 43(2), 113797.

Fukushima H, et al. (2024) Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells. *EBioMedicine*, 102, 105050.